SEC Comment Letter 0000000000-24-009584 to Bone Biologics Corp (BBLG)
Bone Biologics Corp
Date: Aug. 21, 2024 · CIK: 0001419554 · Accession: 0000000000-24-009584
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281494
Letter
August 21, 2024 Jeffrey Frelick Chief Executive Officer Bone Biologics Corp 2 Burlington Woods Drive Suite 100 Burlington, MA 01803 Re:Bone Biologics Corp Registration Statement on Form S-3 Filed August 12, 2024 File No. 333-281494 Dear Jeffrey Frelick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Robert Augustin at 202-551-8483 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:Alexander R. McClean
Show Raw Text
August 21, 2024
Jeffrey Frelick
Chief Executive Officer
Bone Biologics Corp
2 Burlington Woods Drive
Suite 100
Burlington, MA 01803
Re:Bone Biologics Corp
Registration Statement on Form S-3
Filed August 12, 2024
File No. 333-281494
Dear Jeffrey Frelick:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Robert Augustin at 202-551-8483 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Alexander R. McClean